TC
TXMD icon

TFS Capital’s TherapeuticsMD TXMD Stock Holding History

TFS Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-326
Closed -$73K – 1138
2014
Q4 		$73K Sell
326
-701
-68% -$145K 0.01% 936
2014
Q3 		$238K Buy
1,027
+245
+31% +$61.7K 0.02% 822
2014
Q2 		$173K Buy
+782
New +$174K 0.01% 971

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

TFS Capital's TXMD Position: Q1 2015 in Review

TFS Capital sold out of TherapeuticsMD (TXMD) in Q1 2015, closing a stake of 326 shares — an estimated $73K sold.

TFS Capital first reported a position in TXMD in Q2 2014 and held it in 3 quarters. The position peaked at $238K in Q3 2014. 94 funds tracked by Wall St. Rank hold TXMD as of Q1 2015.

  • TFS Capital reported no remaining TherapeuticsMD position as of Q1 2015 after selling out during the quarter.
  • TFS Capital sold 326 TherapeuticsMD shares in Q1 2015, an estimated $73K.
  • TFS Capital first reported a position in TherapeuticsMD in Q2 2014 and held it in 3 quarters.
  • TFS Capital's TherapeuticsMD position peaked at $238K in Q3 2014.
  • 94 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2015.

Based on TFS Capital's 13F filing for Q1 2015, filed 29 Apr 2015.